Determination of 1‐(2‐chloroethyl)‐3‐(2,6‐dioxo‐3‐piperidyl)‐1‐nitrosourea in plasma by negative chemical ionization mass spectrometry

Ronald G. Smith, Lily K. Cheung, Lynn G. Feun, Ti Li Loo

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

A sensitive and specific method for the quantitative determination of a new antitumor agent, 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea, (PCNU) has been developed for the analysis of plasma. This assay involves extraction of the plasma sample, separation of the drug by thin-layer chromatography and mass spectrometric detection of the negative ions derived from the unchanged drug and its 2H4-labeled analog. Ion current profile peaks are obtained when drug samples are introduced into the heated source using a desorption chemical ionization probe. Detection limits are below 1.0 ng ml-1 of plasma. This method has been applied to determine the in vitro rate of decomposition of PCNU in plasma and the plasma clearance of this drug from a cancer patient.

Original languageEnglish (US)
Pages (from-to)404-407
Number of pages4
JournalBiological Mass Spectrometry
Volume10
Issue number7
DOIs
StatePublished - Jul 1983
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine

Fingerprint Dive into the research topics of 'Determination of 1‐(2‐chloroethyl)‐3‐(2,6‐dioxo‐3‐piperidyl)‐1‐nitrosourea in plasma by negative chemical ionization mass spectrometry'. Together they form a unique fingerprint.

  • Cite this